Hepatitis C Vaccines: Are we making progress? | Christopher M. Walker, PhD

International Hepatitis Cure & Eradication Meeting 2015

Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lost in translation: learning from preclinical data | Gerry Davies

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Russian HIV Clinical Series | Natalia Litvinova | 2nd Edition | 15 April

Russian HIV Clinical Series 2021

HAV in a Tertiary Hospital: 2017 Epidemic vs 2009-2016 Period | Andrea Lombardi, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Roundtable Discussion: Hepatitis A in HIV: the French, Italian, and Spanish Perspective | Luz Martin-Carbonero, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Roundtable Discussion: Hepatitis A in HIV: the French, Italian, and Spanish Perspective | Massimo Puoti, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

NAFLD in HIV- infected patients | Juan Macías, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Case on HEV | Antonio Rivero-Juarez, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Debate: TDF vs. TAF in HBV management | Douglas Dieterich, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Debate: TDF vs. TAF in HBV management | Mark Nelson, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Decrease in HCV Coinfection in Individuals Newly Diagnosed with HIV-1 in Germany, January 2016 - December 2017 | Patrycja Machnowska

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Characterization of Patients Treated with Hepatitis C - is HIV a Burden? Analysis of an Individual Experience | Cristina Valente

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Epidemiological Characteristics and Factors Contributing to the Development of Liver Fibrosis in HIV/HCV-Coinfected Patients in Ukraine | Tatyana Kyrychenko

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Hepatitis C Diagnostic - Barrier to Effective Linkage to Care within Georgian Hepatitis C Elimination Program | Guranda Jikia, MD, MPH

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HBV managment in HIV patients | Karine Lacombe, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HCV care after cure | Raffaele Bruno, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Fibrosis Markers and Cirrhosis management in HIV patients | Marion Peters, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

NAFLD: diagnostics, management and screening | Juan Macías, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Liver care in HIV - management of abnormal LFTs | Juan Berenguer, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

HBV: diagnostics, management and screening | Marion Peters, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018